We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Smarter Blood Tests Deliver Faster Diagnoses and Improved Outcomes

By LabMedica International staff writers
Posted on 19 Nov 2024
Print article
Image: Small molecule modulation of protein corona significantly enhances deep plasma proteome profiling (Photo courtesy of Mahmoudi Group)
Image: Small molecule modulation of protein corona significantly enhances deep plasma proteome profiling (Photo courtesy of Mahmoudi Group)

It has long been established that the earlier a disease is detected, the better the chances for a positive patient outcome. A novel method now offers an in-depth analysis of proteins in plasma, uncovering biomarkers that can help researchers and eventually clinicians identify diseases at an earlier stage.

This pioneering methodology for deep analysis of proteins in plasma was developed by a multidisciplinary team of researchers from Michigan State University (East Lansing, MI, USA), in collaboration with other experts. The new approach minimizes the interference from common blood proteins, making it possible to detect lesser-known, low-abundance proteins that are often key in diagnosing diseases. By introducing small molecules into the blood sample, these important proteins are exposed on the surface of nanoparticles, enhancing their visibility for analysis through mass spectrometry—a technique that separates and examines ionized particles using electric and magnetic fields.

This breakthrough testing method, published in Nature Communications, contributes to the advancement of precision medicine. Unlike the traditional "one-size-fits-all" treatment approach, precision medicine customizes healthcare for an individual's genetics, environment, and lifestyle, offering more targeted and effective solutions. This approach has shown particular promise in fields like cancer research, where tumor genetic profiling can result in improved outcomes and reduced side effects.

“Our innovative approach significantly reduces the masking effects of highly abundant plasma proteins, which often hinder the detection of critical biomarkers in human plasma,” said Morteza Mahmoudi, associate professor in the Department of Radiology and Precision Health Program in the MSU College of Human Medicine. “By minimizing these interactions, we can increase the visibility and identification of low-abundance proteins, making it easier to detect important biomarkers that would otherwise remain hidden. This enhancement leads to improved diagnostic capabilities, allowing for more precise and earlier detection of diseases.”

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.